Education
About Us
Working with TipRanks
Follow Us
Appili Therapeutics Inc Class A (TSE:APLI)
TSX:APLI
APLI Stock Chart & Stats
C$0.02
>-C$0.01(-14.29%)
At close: 4:00 PM EST
C$0.02
>-C$0.01(-14.29%)
Day’s Range― - ―
52-Week RangeC$0.01 - C$0.04
Previous CloseN/A
Volume36.33K
Average Volume (3M)72.91K
Market Cap
C$2.57M
Enterprise ValueC$14.67M
Total Cash (Recent Filing)C$212.75K
Total Debt (Recent Filing)C$12.46M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding128,366,120
10 Day Avg. Volume40,186
30 Day Avg. Volume72,908
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.39
Price to Sales (P/S)5.13
P/FCF Ratio-1.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Reported Revenue GrowthSustained high percentage revenue growth from a small base signals improving program funding or milestone recognition, indicating the business is beginning to monetize development progress. Over 2-6 months this trend can translate into more visible partnership or grant revenue, improving operational runway if sustained.
High Reported Gross MarginHigh gross margins point to favorable product-level economics if candidates reach commercialization or are licensed. This structural characteristic supports margin scalability because biotech COGS are often low vs. price; once revenue scales, high gross margins materially aid progress to sustainable profitability.
Access To Grants And Improved Cash FlowA diversified funding mix—government grants, collaborations and improving cash flow—reduces sole reliance on dilutive equity. Structural access to non-dilutive support plus incremental cash-flow improvement extends runway and enables continued clinical advancement over the medium term without immediate commercial revenues.
Bears Say
Negative Shareholders' EquityNegative shareholders' equity and relatively high debt versus minimal assets indicate a thin, stressed balance sheet that limits strategic flexibility. Over the next several months this elevates refinancing and covenant risk, increases likelihood of dilutive financing, and constrains bargaining power with partners or acquirers.
Persistent Operating LossesMaterial and ongoing operating losses reflect that R&D and operating spend continue to exceed receipts. This structural loss profile necessitates continued external funding, limits internal reinvestment capacity, and raises execution risk if financing windows tighten or if clinical milestones slip.
Very Small Absolute Revenue BaseDespite strong percentage growth, absolute revenue remains negligible, implying commercial validation is lacking. This small base means the company is not yet self-sustaining; durability of operations depends on future milestone payments, grants, or financings rather than recurring product income.
Appili Therapeutics Inc Class A News
APLI FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was C$0.01 and its highest was C$0.04 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is C$2.57M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Jul 01, 2026 which is in 128 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Feb 12, 2026. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 128,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in TSE:APLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.